Brain structural and functional recovery following initiation of combination antiretroviral therapy

Journal of NeuroVirology

Volumn 18, Issue 5, 2012, Pages 423-427

  Becker, James T ^a,f   Cuesta, Pablo ^b   Fabrizio, Melissa ^a   Sudre, Gustavo ^c   Vergis, Emanuel N ^a   Douaihy, Antoine ^a   Bajo, Ricardo ^b   Schubert, Allie ^a   Lopez, Oscar L ^a   Parkkonen, Lauri ^d,e   Maestu, Fernando ^b   Bagic, Anto ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^c CARNEGIE MELLON UNIVERSITY   (United States)

^d AALTO UNIVERSITY   (Finland)

^e Elekta Oy   (Finland)

^f Neuropsychological Research Program   (United States)

Author keywords

Functional connectivity; HIV disease; Magnetoencephalography; Neuroaids

Indexed keywords

EFAVIRENZ; EMTRICITABINE; TENOFOVIR;

ADULT; ARTICLE; BRAIN FUNCTION; BRAIN SIZE; CASE REPORT; CD4 LYMPHOCYTE COUNT; COGNITION; HIV ASSOCIATED DEMENTIA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAGNETOENCEPHALOGRAPHY; MALE; NERVE CELL NETWORK; NEUROPSYCHOLOGICAL TEST; NUCLEAR MAGNETIC RESONANCE IMAGING; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL;

AIDS DEMENTIA COMPLEX; ANTI-HIV AGENTS; BRAIN; COGNITION; DRUG THERAPY, COMBINATION; HUMANS; MAGNETOENCEPHALOGRAPHY; MALE; MIDDLE AGED; NERVE NET; NEUROPSYCHOLOGICAL TESTS;

EID: 84867325042     PISSN: 13550284     EISSN: 15382443     Source Type: Journal    
DOI: 10.1007/s13365-012-0115-0     Document Type: Article

References (14)

1. Becker JT, Fabrizio M, Sudre G et al (2012a) Potential utility of resting-state magnetoencephalography power spectra as a biomarker of CNS abnormality in HIV disease. J Neurosci Methods 206:176-182
2. Becker JT, Bajo R, Fabrizio M et al. (2012) Functional connectivity measured with magnetoencephalography identifies persons with HIV disease. Brain Imaging Behav doi:10.1007/s11682-012-9149-4
3. Crawford JR, Garthwaite PH, Porter S (2010) Point and interval estimates of effect sizes for the case-controls design in neuropsychology: rationale, methods, implementations, and proposed reporting standards. Cogn Neuropsychol 27(3):245-260
4. Cysique LA, Brew BJ, Halman M et al (2005) Undetectable cerebrospinal fluid HIV RNA and beta-2 microglobulin do not indicate inactive AIDS dementia complex in highly active antiretroviral therapytreated patients. J Acquir Immune Defic Syndr 39(4):426-429
5. Dore GJ, Correll PK, Li Y, Kaldor JM, Cooper DA, Brew BJ (1999) Changes to AIDS dementia complex in the era of highly active antiretroviral therapy. AIDS 13(10):1249-1253
6. Heaton RK, Taylor MJ (2004) Revised comprehensive norms for an expanded Halstead-Reitan Battery: demographically adjusted neuropsychological norms for African American and Caucasian adults. Psychological Assessment Resources, Odessa
7. Hlavácková-Schindler K, Paluš M, Velmejka M, Bhattacharya J (2007) Causality detection based on information-theoretic approaches in time series analysis. Phys Rep 441(1):1-46
8. Mueller SG, Weiner MW, Thal LJ et al (2005) The Alzheimer's disease neuroimaging initiative. Neuroimaging Clin N Am 15(4):869-877
9. Price RW, Epstein LG, Becker JT et al (2007) Biomarkers of HIV-1 CNS infection and injury. Neurology 69(18):1781-1788
10. Sacktor N, Lyles RH, Skolasky R et al (2001) HIV-associated neurologic disease incidence changes: Multicenter AIDS Cohort Study, 1990-1998. Neurology 56:257-260
11. Sacktor N, McDermott MP, Marder K et al (2002) HIV-associated cognitive impairment before and after the advent of combination therapy. J Neurovirol 8:136-142
12. Simioni S, Cavassini M, Annoni JM et al (2010) Cognitive dysfunction in HIV patients despite long-standing suppression of viremia. AIDS 24(9):1243-1250
13. Smith SM, Zhang Y, Jenkinson M, Chen J, Matthews PM, Federico A, De Stefano N (2002) Accurate, robust and automated longitudinal and cross-sectional brain change analysis. NeuroImage 17(1):479-489
14. Woods SP, Rippeth JD, Frol AB et al (2004) Interrater reliability of clinical ratings and neurocognitive diagnoses in HIV. J Clin Exp Neuropsychol 26(6):759-778